GSI-136

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H18ClNO3S2
Molecular Weight	311.849
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(CC)[C@@H](CO)NS(=O)(=O)C1=CC=C(Cl)S1

InChI

InChIKey=PYZFRRVBPNGCBX-SECBINFHSA-N

InChI=1S/C11H18ClNO3S2/c1-3-8(4-2)9(7-14)13-18(15,16)11-6-5-10(12)17-11/h5-6,8-9,13-14H,3-4,7H2,1-2H3/t9-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.drugbank.ca/drugs/DB12819 | https://clinicaltrials.gov/ct2/show/NCT00718731 | https://clinicaltrials.gov/ct2/show/NCT00719394

GSI-136 is an amyloid protein secretase inhibitor that has been tested for treatment of Alzheimer Disease. This γ-Secretase inhibitor was evaluated in a phase I clinical trial to determine its safety and tolerability in healthy subjects after administration of single oral doses.

Originator

Approval Year

PubMed

Title	Date	PubMed
(S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor.	2009-02-01	19097890

Patents

Name

Type

Language

GSI-136

Common Name

English

2-THIOPHENESULFONAMIDE, 5-CHLORO-N-((1S)-2-ETHYL-1-(HYDROXYMETHYL)BUTYL)-

Preferred Name

English

Code System Code Type Description

FDA UNII

51JV4753AD